Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Next Previous
Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer

    • Most Recent Events

    • 08 Jun 2021 Results of meta analysis of Four eligible phase III studies (REFLECT, SHARP, Asia-Pac and IMbrave150) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 12 Sep 2017 Results of exploratory analysis assessing overall survival by using baseline platelet count from three studies (SHARP, AP, and RESORCE) presented at the 42nd European Society for Medical Oncology Congress
    • 21 Jan 2017 Results (n=828) from NCT00105443 and NCT00492752 trials assessing the correlation between time to progression (TTP) and overall survival, presented at the 2017 Gastrointestinal Cancers Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top